Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics

Pharmacogenomics Journal

Volumn 2, Issue 6, 2002, Pages 400-407

  Nikoloff, D ^a   Shim, J C ^b   Fairchild, M ^a   Patten, N ^a   Fijal, B A ^a   Koch, W H ^a   MacPherson, A ^c   Flockhart, D ^d   Yoon, Y R ^e   Yoon, J S ^f   Kim, Y H ^f   Shin, J G ^e  

^a ROCHE MOLECULAR SYSTEMS   (United States)

^b Inje University College of Medicine   (South Korea)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Inje University College of Medicine   (South Korea)

^f Chonnam National University Medical School   (South Korea)

Author keywords

CYP2D6; Genotyping; Tardive dyskinesia

Indexed keywords

ANTIARRHYTHMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450 2D6; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; NORTRIPTYLINE; OLANZAPINE; PERPHENAZINE; PIMOZIDE; RISPERIDONE; THIORIDAZINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; ZUCLOPENTHIXOL;

ADULT; AGED; ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA MICROARRAY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC ASSOCIATION; GENETIC CODE; GENETIC SCREENING; GENOTYPE; HUMAN; KOREA; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA; WILD TYPE;

ADOLESCENT; ADULT; AGED; CYTOCHROME P-450 CYP2D6; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KOREA; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SCHIZOPHRENIA; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 12244299890     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500138     Document Type: Article

References (37)

1. Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54(4): 133-139.
2. Casey DE. Tardive dyskinesia and atypical antipsychotic drugs. Schizophr Res 1999; 35(Suppl): S61-S66.
3. Wszola BA, Newell KM, Sprague RL. Risk factors for tardive dyskinesia in a large population of youths and adults. Exp Clin Psychopharmacol 2001; 9(3): 285-296.
4. Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50(9): 723-733.
5. Morgenstern H, Glazer WM, Gibowski LD, Holmberg S. Predictors of tardive dyskinesia: results of a cross-sectional study in an outpatient population. J Chronic Dis 1987; 40(4): 319-327.
6. Otani K, Aoshima T. Pharmacogenetics of classical and new anti-psychotic drugs. Ther Drug Monit 2000; 22(1): 118-121.
7. Marez D, Legrand M, Sabbagh N, Guidice JM, Spire C, Lafitte JJ et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 1997; 7(3): 193-202.
8. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37: 269-296.
9. Wang SL, Huang JD, Lai MD, Liu BH, Lai ML. Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects: polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993; 53(4): 410-418.
10. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991; 40(6): 553-556.
11. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM et al. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine and S-mephenytoin. Clin Pharmocol Ther 1992; 51(4): 388-397.
12. Brockmoller J, Kirchheiner J, Meisel C, Roots I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics 2000; 1(2): 125-151.
13. Kapitany T, Meszaros K, Lenzinger E, Schindler SD, Barnas C, Fuchs K et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr Res 1998; 32(2): 101-106.
14. Andreassen OA, MacEwan T, Gulbrandsen AK, McCreadie RG, Steen VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology (Berl) 1997; 131(2): 174-179.
15. Ellingrod VL, Schultz SK, Arndt S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal involuntary movement scale (AIMS) score. Psychiatr Genet 2000; 10(1): 9-11.
16. Armstrong M, Daly AK, Blennerhassett R, Ferrier N, Idle JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry 1997; 170: 23-26.
17. Arthur H, Dahl ML, Siwers B, Sjoqvist F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol 1995; 15(3): 211-216.
18. Dahl ML, Yue QY, Roh HK, Johansson I, Sawe J, Sjoqvist F et al. Genetic analysis of the CYP2D locus in relation to debrisoquine hydroxylation capacity in Korean, Japanese and Chinese subjects. Pharmacogenetics 1995; 5(3): 159-164.
19. Roh HK, Dahl ML, Johansson I, Ingelman-Sundberg M, Cha YN, Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. Pharmacogenetics 1996; 6(5): 441-447.
20. Potkin SG, Shen Y, Pardes H, Phelps BH, Zhou D, Shu L et al. Haloperidol concentrations elevated in Chinese patients. Psychiatry Res 1984; 12(2): 167-172.
21. Someya T, Suzuki Y, Shimoda K, Hirokane G, Morita S, Yokono A et al. The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psychiatry Clin Neurosci 1999; 53(5): 593-597.
22. Roh HK, Chung JY, Oh DY, Park CS, Svensson JO, Dahl ML et al. Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol 2001; 52(3): 265-271.
23. Suzuki Y, Someya T, Shimoda K, Hirokane G, Morita S, Yokono A et al. Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol. Ther Drug Monit 2001; 23(4): 363-368.
24. Llerena A, Dahl ML, Ekqvist B, Bertilsson L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit 1992; 14(3): 261-264.
25. Ohmori O, Suzuki T, Kojima H, Shinkai T, Terao T, Mita T et al. Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr Res 1998; 32(2): 107-113.
26. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjoqvist F, Ingelman-Sundberg M. Genetic analysis of the Chinese cytochrome P4502D locus: characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 1994; 46(3): 452-459.
27. Lam LC, Garcia-Barcelo MM, Ungvari GS, Tang WK, Lam VK, Kwong SL et al. Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry 2001; 34(6): 238-241.
28. Rey MJ, Schulz P, Costa C, Dick P, Tissot R. Guidelines for the dosage of neuroleptics. I: Chlorpromazine equivalents of orally administered neuroleptics. Int Clin Psychopharmacol 1989; 4(2): 95-104.
29. Guy, W. Assessment Manual for Psychopharmacology. Publication ADM, U.S. Department of Health, Education and Welfare, 1976.
30. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39(4): 486-487.
31. Wang SL, Lai MD, Huang JD. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese. Drug Metab Dispos 1999; 27(3): 385-388.
32. Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T et al. A new CYP2D6 allele with a nine base insertion in exon 9 in a Japanese population associated with poor metabolizer phenotype. Pharmacogenetics 1996; 6(5): 395-401.
33. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen AL, Idle JR et al. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995; 5(4): 215-223.
34. Raimundo S, Fischer J, Eichelbaum M, Griese EU, Schwab M, Zanger UM. Elucidation of the genetic basis of the common 'intermediate metabolizer' phenotype for drug oxidation by CYP2D6. Pharmacogenetics 2000; 10(7): 577-581.
35. Claassen JD, Pascoe N, Schatzberg AF, Murphy Jr GM. Rapid detection of the C-1496G polymorphism in the CYP2D6*2 allele. Clin Chem 2001; 47(12): 2153-2155.
36. Murphy Jr GM, Pollock BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH et al. CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 2001; 25(5): 737-743.
37. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999; 9(6): 669-682.